Oppenheimer Begins Coverage on CAMP4 Therapeutics (NASDAQ:CAMP)

Investment analysts at Oppenheimer began coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a report released on Monday, Marketbeat.com reports. The firm set an “outperform” rating and a $15.00 price target on the Wireless communications provider’s stock. Oppenheimer’s price objective would indicate a potential upside of 278.79% from the stock’s current price.

Several other research analysts have also weighed in on CAMP. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. UBS Group set a $15.00 price target on CAMP4 Therapeutics in a research report on Friday, August 14th. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Chardan Capital decreased their price objective on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.86.

CAMP4 Therapeutics Stock Performance

Shares of NASDAQ:CAMP opened at $3.96 on Monday. The company has a 50 day moving average price of $4.18 and a two-hundred day moving average price of $4.23. The company has a market capitalization of $248.49 million, a PE ratio of -1.71 and a beta of 0.27. CAMP4 Therapeutics has a 52 week low of $2.86 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The firm had revenue of $1.78 million for the quarter. On average, sell-side analysts forecast that CAMP4 Therapeutics will post -0.57 earnings per share for the current year.

Insider Buying and Selling at CAMP4 Therapeutics

In other news, Director Richard A. Young bought 16,378 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $1.65 per share, with a total value of $27,023.70. Following the acquisition, the director owned 186,388 shares in the company, valued at $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Andrew J. Schwab sold 400,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the sale, the director owned 2,033,270 shares of the company’s stock, valued at $8,214,410.80. This trade represents a 16.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders bought 46,031 shares of company stock worth $99,051 and sold 593,613 shares worth $2,504,037. Corporate insiders own 21.69% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CAMP. Jupiter Topco LLC acquired a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $27,581,000. 5AM Venture Management LLC bought a new position in CAMP4 Therapeutics during the second quarter worth $25,647,928. Trails Edge Capital Partners LP acquired a new position in shares of CAMP4 Therapeutics in the second quarter valued at $8,446,935. BlackRock Inc. acquired a new position in shares of CAMP4 Therapeutics in the second quarter valued at $7,185,000. Finally, EcoR1 Capital LLC bought a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at about $1,992,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.